Samsung Biologics Reports Third Quarter 2026 Financial Results
The contract development and manufacturing company cited stronger plant output and its first revenue from the Rockville facility as it expands capacity and funding plans.
- On October 21, 2026, Samsung Biologics reported third-quarter revenue of 1,490 billion KRW and operating profit of 640.1 billion KRW, though net profit declined 21.2 percent to 391.1 billion KRW.
- Full-Scale operations at four plants in Songdo, South Korea, alongside production ramp-ups at a fifth facility and the company's first biomanufacturing site in Rockville, Maryland, drove the revenue increase.
- Samsung Biologics updated its 2026 annual revenue growth guidance to 20 percent, up from its previous range of 15 to 20 percent, reflecting confidence in operational performance and growth trajectory.
- To fund strategic investments including the planned PolyPeptide Group acquisition, Samsung Biologics announced a KRW 3 trillion rights offering supporting future manufacturing capacity expansion.
- Cumulative contract orders for the year exceeded 21.9 billion USD, reflecting sustained demand for CDMO services and reinforcing the company's ability to serve clients across an expanding global network.
17 Articles
17 Articles
Samsung Biologics Q3 net income down 21.2% to $295.2 mil.
Samsung Biologics, the biotech arm of Samsung Group, on Wednesday reported its third-quarter net profit of 391.1 billion won ($295.2 million), down 21.2 percent from a year earlier. The contract development and manufacturing organization (CDMO) service provider, which offers comprehensive development and manufacturing solutions, said in a regulatory filing that it posted 640.1 billion won in operating profit for the quarter, compared with 633.5 …
Samsung Biologics achieved record-breaking quarterly performance in its CDMO business in the third quarter, recording 1.4903 trillion won in revenue and 640.1 billion won in operating profit. This result was driven by the full operation of the Songdo plant and the reflection of revenue from the Rockville facility in the U.S., and the company raised its annual revenue growth forecast to 20%.
(Seoul = Yonhap News) Reporter Shin Seon-mi = Samsung Biologics [207940] reported a consolidated operating profit of 640.1 billion won for the third quarter of this year, up 1% from the same period last year...
Samsung Biologics Reports Third Quarter 2026 Financial Results
Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billionPlant 5 ramp-up and U.S. manufacturing operations contribute to earnings performanceRaised 2026 revenue growth guidance to 20% while advancing strategic investments in portfolio and capacity expansion
Coverage Details
Bias Distribution
- 45% of the sources are Center, 44% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
